The Association Isoflurane-verapamil Causes Regional Left-ventricular Dyssynchrony in the Dog

Michel Videoq, M.D.,* Charles C. Arvieux, M.D.,† James G. Ramsay, B.Sc., M.D.,‡ Pierre Foëx, M.D., D.Phil.,§ J. Gilbert Stone, M.D.,‖ W. Alan Ryder,** Lee A. Jones††

In ten dogs anesthetized with 1% inspired isoflurane, the effect of low-dose verapamil on global and regional myocardial function was studied. The administration of verapamil resulted in no change in heart rate or blood pressure, but left ventricular stroke work, peak power, LV dP/dt max, and aortic blood acceleration were significantly reduced, while coronary blood flow remained unchanged. End-diastolic length increased in territory supplied by both left anterior descending (LAD) and left circumflex (LC) artery, but a significant decrease in systolic shortening occurred in the LAD segment only. Dyssynchrony of wall motion, characterized by post-systolic shortening, accompanied in three animals by a small amount of systolic lengthening, appeared with the administration of verapamil and was more pronounced in the LAD segment. Such patterns of wall motion have usually been attributed to myocardial ischemia. In the absence of significant reduction in coronary blood flow, and in the presence of a delay in onset of shortening and lengthening, these patterns of wall motion are more likely to reflect dyssynchrony of regional function than ischemia. (Key words: Anesthesics, Inhalation: isoflurane. Calcium channel blockers: verapamil. Heart: regional ventricular function.)

The interactions of calcium channel blockers, especially verapamil, with inhalation anesthetics have been studied extensively. Comparisons of the interactions between verapamil and halothane, enflurane, or isoflurane have shown that, at low plasma concentrations of verapamil (less than 100 ng·ml⁻¹), verapamil-isoﬂurane causes less global cardiac depression than verapamil-enflurane or verapamil-halothane.¹ The negative inotropic effect of verapamil is already present at plasma concentrations as low as 35 ng·ml⁻¹, in open chest preparations,² but is relatively small even at much higher concentrations in closed chest preparations.³⁻⁴

In this study, we evaluated the effect of a low dose of intravenous verapamil on global and regional left ventricular function, during steady-state isoflurane anesthesia, in order to determine whether dyssynchrony of contraction as described with the association halothane-verapamil⁵ was also present with isoflurane-verapamil.

Methods

Ten mongrel dogs weighing between 15 and 21 kg were premedicated with morphine sulfate (1 mg·kg⁻¹) intramuscularly. Anesthesia was induced with thiopentone 10 mg·kg⁻¹, the trachea was intubated, and constant volume intermittent positive pressure ventilation was instituted with a nitrogen:oxygen (2:1) mixture, with carbon dioxide added to maintain normocarbia. During surgical preparation, anesthesia was maintained with halothane. Temperature, monitored at the mid esophagus, was maintained between 37 and 38°C by a heating element incorporated in the operating table.

An intravenous cannula was placed in the femoral vein for infusion of 0.9% saline at a constant rate of 4 ml·kg⁻¹·h⁻¹ by an infusion pump, and a rigid 14-gauge polyethylene catheter was inserted in the left common carotid artery and advanced to within 1 cm of the aortic valve for measurement of systemic arterial pressure (Statham pressure transducer).

A left thoracotomy was performed, the fifth and sixth ribs excised, and the heart exposed and suspended in a pericardial cradle. A cannula was inserted into the pulmonary artery via the outflow tract of the right ventricle for determination of cardiac output (dye dilution), and a rigid 14-gauge cannula was inserted into the left ventricle via a stab wound in the apical dimple for measurement of pressure (Statham pressure transducer).

The aortic root was dissected free of its fat pad, and an appropriately sized electromagnetic flow transducer (SEM 230, SE laboratories) was placed around it. In the first seven dogs, the left anterior descending coronary artery (LAD) was then dissected free distal to the second major diagonal branch, and an electromagnetic flow transducer (SEM 230, SE laboratories) was placed around it.
Two pairs of ultrasonic piezo-electric crystals were inserted at the level of the subendocardium, parallel to the short axis of the heart. One pair was implanted in the apical area supplied by the left anterior descending coronary artery (LAD), and the other in the upper part of the free wall of the left ventricle supplied by the left circumflex coronary artery (LC).

Regional myocardial function was assessed by continuous measurement of segment length between each pair of crystals, based on the transit time of ultrasound. The transit time signal may be converted into a length signal as ultrasound travels through the myocardium at a constant velocity of 1.56 mm·μs⁻¹.

Regional dimensions were measured as follows: end-diastolic length (EDL) was measured at the time of the beginning of the sharp up-slope of the first derivative of the left ventricular pressure (LV dP/dt) signal; end-systolic length (EEL) was measured at the time of closure of the aortic valve, as indicated by the time when aortic flow tracing crosses the zero line; and maximum and minimum lengths during systole (LmaxS and LminS), and minimum length during diastole (LminD) were also measured. Percentage of systolic and post-systolic shortening (% SS, % PSS) were derived from these lengths as follows:

% SS = \(\frac{(L \text{ max } S - L \text{ min } S)}{L \text{ max } S} \times 100\)

% PSS = \(\frac{(EEL - L \text{ min } D)}{(L \text{ max } S - L \text{ min } D)} \times 100\)

In a normal segment, L min S occurs at the end of systole, and L max S occurs at the end of diastole or just at the beginning of systole (due to atrial contraction). However, in abnormal segments, L min may occur during diastole. Similarly, an increase in length may develop after aortic valve opening, in which case there is systolic bulge. The simultaneous recordings of left ventricular pressure and regional dimensions makes it possible to examine their time course and to obtain pressure-length loops. A normal trace is shown in figure 1, together with aortic and left-ventricular pressures. The loop plotted beside the trace shows the dynamic relationship between length and pressure, and the stages of the cardiac cycle with reference to opening and closure of the aortic valve. Abnormal patterns of wall motion are displayed in figure 2, showing systolic bulge and post-systolic shortening.

The onset of regional shortening and lengthening was measured with reference to the time when the LVdP/dt signal reached 200 mmHg·s⁻¹.

ECG (lead II), PR interval, aortic and left ventricular pressures, aortic flow, and aortic blood acceleration (differentiation of the flow signal) were recorded simultaneously, together with the length signals. Stroke volume was obtained by on-line integration of the flow signal, and was calibrated by triplicate determination of cardiac output by dye dilution. Derived hemodynamic variables were calculated using conventional methods.

The signals were recorded on a monograph 81 eight channel recorder (ELEMA Schonander, Stockholm, Sweden) at a paper speed of 250 mm·s⁻¹.

As an index of early global diastolic function, the time constant of isovolumic relaxation (T relax) was calculated. This is achieved by regression analysis of the logarithms of instantaneous values of pressure against time, for the period from aortic valve closure to the time when LV pressure reaches 10 mmHg above LVEDP.
Fig. 2. Two examples of dysynchrony of contraction. A. The length trace (left) shows that Lmin is shorter than ESL and occurs after aortic valve closure (post-systolic shortening). Because of post-systolic shortening, the loop bulges to the left. Abbreviations as in figure 1. B. The length trace (left) shows that Lmax is greater than EDL (systolic lengthening) and Lmin is shorter than ESL and occurs after aortic valve closure (post-systolic shortening). These changes in regional contraction cause the pressure-length loop to "tilt" to the right and later to bulge to the left. Abbreviations as in figure 1.

Blood samples for measurement of plasma verapamil concentration by high-pressure liquid chromatography were obtained at the end of the loading dose, and 30 min after the start of the maintenance infusion. Statistical analysis was performed using paired Student's t tests, the null hypothesis being rejected when P was less than 0.05.

Protocol

After completion of the surgical preparation, halothane was replaced by isoflurane (1% inspired), delivered by a Cyprane vaporizer calibrated by mass spectrometry. Blood gases were analyzed and, where necessary, ventilation adjusted to ensure normocarbia, and sodium bicarbonate given to control metabolic acidosis. An hour was allowed to elapse after the introduction of isoflurane before control measurements were recorded. At the time halothane was replaced by isoflurane, surgery had been completed, and, for the duration of the study, the animals did not breathe or move, even though muscle relaxants were not administered.

Verapamil was then given intravenously as a loading dose of 250 μg·kg⁻¹ over 30 min, followed by a maintenance dose of 60 μg·kg⁻¹·h⁻¹. The effects of verapamil were recorded 30 min after the start of the maintenance dose.
TABLE 1. Effect of Verapamil iv Infusion on LV Global Hemodynamics, Diastolic Relaxation, and LAD Coronary Perfusion in Ten Dogs (Mean ± SEM)

<table>
<thead>
<tr>
<th>Control</th>
<th>Verapamil</th>
</tr>
</thead>
<tbody>
<tr>
<td>HR (b · min⁻¹)</td>
<td>113 ± 5</td>
</tr>
<tr>
<td>MAP (mmHg)</td>
<td>93.2 ± 5.1</td>
</tr>
<tr>
<td>PR interval (ms)</td>
<td>92.2 ± 3.8</td>
</tr>
<tr>
<td>SV (ml · kg⁻¹)</td>
<td>1.19 ± 0.09</td>
</tr>
<tr>
<td>CO (ml · min⁻¹ · kg⁻¹)</td>
<td>131.5 ± 9.4</td>
</tr>
<tr>
<td>Aortic blood accel. (ml · s⁻²)</td>
<td>6389 ± 514</td>
</tr>
<tr>
<td>LV stroke work (mW)</td>
<td>14.6 ± 1.1</td>
</tr>
<tr>
<td>LV peak power (mW)</td>
<td>3424 ± 280</td>
</tr>
<tr>
<td>LV dP/dt max (mmHg · s⁻¹)</td>
<td>1603 ± 115</td>
</tr>
<tr>
<td>SVR (dyne · s⁻¹ · cm⁻⁵)</td>
<td>2876 ± 203</td>
</tr>
<tr>
<td>LVEDP (mmHg)</td>
<td>4.85 ± 0.5</td>
</tr>
<tr>
<td>Negative LV dP/dt (mmHg · s⁻¹)</td>
<td>1885 ± 119</td>
</tr>
<tr>
<td>T relax (ms)</td>
<td>26.0 ± 1.2</td>
</tr>
<tr>
<td>LAD blood flow (ml · min⁻¹ · 100 g⁻¹)</td>
<td>81.2 ± 6.3</td>
</tr>
<tr>
<td>Coronary perfusion pressure (mmHg)</td>
<td>75.9 ± 4.4</td>
</tr>
</tbody>
</table>

LAD = left anterior descending coronary artery.
* P < 0.05.
† P < 0.01.
‡ P < 0.0001.

Results

PLASMA VERAPAMIL CONCENTRATIONS

The mean plasma concentration of verapamil, at the end of the loading dose, was 68.7 ng · ml⁻¹ (SD ± 20.6), 45.5 ng · ml⁻¹ (SD ± 10.6) 30 min, and 49.6 ng · ml⁻¹ (SD ± 11.2) 90 min after the start of the maintenance dose. Norverapamil was not detectable in these samples.

GLOBAL HEMODYNAMICS

Hemodynamic data are shown in table 1. The administration of verapamil produced no significant changes in heart rate and arterial pressure, but a significant increase in PR interval was observed. Global cardiac performance was significantly depressed. There was a 20% decrease in stroke volume (P < 0.005), a 15% decrease in cardiac output (P < 0.015), and significant decreases in aortic blood acceleration, LV stroke work, LV peak power, and LV dP/dt max. At the same time, systemic vascular resistance and LVEDP increased significantly. Relaxation was impaired, as evidenced by an increase in T relax and a decrease in peak negative LVEDP/dt.

Coronary blood flow and coronary perfusion pressure remained unchanged.

REGIONAL FUNCTION

A significant increase in end-diastolic length in both LAD and LC territories was observed with verapamil, suggesting ventricular dilation.

A 36% decrease in the percentage of systolic shortening (P < 0.0001) occurred in the LAD segment, but not in the LC segment. Post-systolic shortening appeared in both segments with the administration of verapamil. In addition, systolic lengthening (bulge) was observed in three dogs, being more marked in the LAD territory.

There was a significant effect of verapamil on the time course of regional contraction. The onset of systolic shortening was significantly delayed in the LAD segment, and the onset of diastolic lengthening delayed in both segments.

Discussion

The plasma concentrations of verapamil obtained in these experiments were slightly higher than those reported by Kates et al.² (about 45 ng · ml⁻¹ compared to 35 ng · ml⁻¹), but correspond to the lowest levels in the study by Kapur et al.¹ and Campos and Kapur.¹⁰

During steady-state isoflurane anesthesia, verapamil increased atrio-ventricular conduction time and caused significant reductions of all indices of global left ventricular performance, accompanied by a small but significant increase in LVEDP. The negative inotropic and inotropic effects of verapamil were accompanied by

TABLE 2. Effect of Verapamil iv Infusion on Regional Hemodynamics in Ten Dogs (Mean ± SEM)

<table>
<thead>
<tr>
<th></th>
<th>Apical Region</th>
<th>Basal Region</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Control</td>
<td>Verapamil</td>
</tr>
<tr>
<td>EDL (mm)</td>
<td>13.1 ± 0.6</td>
<td>13.6 ± 0.6†</td>
</tr>
<tr>
<td>% SS (%)</td>
<td>17 ± 1.7</td>
<td>10.9 ± 2‡</td>
</tr>
<tr>
<td>% PSS (%)</td>
<td>0</td>
<td>25.3 ± 8.3‡</td>
</tr>
<tr>
<td>syst. bulge (mm)</td>
<td>0</td>
<td>0.07 ± 0.03*</td>
</tr>
<tr>
<td>short. delay (ms)</td>
<td>66.6 ± 3.2</td>
<td>86 ± 6.3†</td>
</tr>
<tr>
<td>lengt. delay (ms)</td>
<td>250 ± 20</td>
<td>300 ± 10†</td>
</tr>
</tbody>
</table>

EDL = end-diastolic length; SS = systolic shortening; PSS = postsystolic shortening.
* P < 0.05.
† P < 0.01.
‡ P < 0.001.
an increase in systemic vascular resistance and a reduction of cardiac output. These findings are in agreement with those of Kates et al.\textsuperscript{2} who used a canine cardiopulmonary bypass preparation but differ from those of Kapur et al.\textsuperscript{1} who used an intact animal preparation. Similarly, our observations differ from those of Chelly et al.\textsuperscript{2} and Rogers et al.,\textsuperscript{4} who showed moderate depression of cardiac performance when infusions of verapamil were administered during halothane, enflurane, or isoflurane anesthesia, even though verapamil plasma levels were higher than in this study. In an open-chest preparation, the effects of positive inotrope interventions can be expected to be blunted and those of negative inotrope interventions to be exaggerated.\textsuperscript{11} This may explain why our observations and those of Kapur et al.\textsuperscript{1} differ. However, acute, invasive preparations may be more like the clinical surgical situation, particularly thoracic surgery, than the non-invasive, non-stimulated preparation without any surgery. With the low dose of verapamil used in this study, atrio-ventricular dissociation would not be expected to develop and, indeed, only an increase in PR interval was observed.

Kates et al.\textsuperscript{2} did examine regional function, but reported their findings solely in terms of regional systolic shortening. They used ultrasonic length detectors placed in the mid-wall of the left ventricle, and found that the addition of low-dose verapamil to isoflurane (1.05\% end-tidal) reduced systolic shortening from 16\% to about 12\%. This is similar to the effect we have observed in the apical region, where shortening was reduced from 17\% to 11\% by the addition of verapamil. In the upper part of the left ventricular wall, shortening was not significantly modified. In their extensive investigations of the interactions between calcium blocking drugs and inhalational anesthetics, Chelly et al.\textsuperscript{5} and Rogers et al.\textsuperscript{6} examined regional ventricular function in terms of maximal length change from end-diastolic length. Reductions in absolute shortening caused by verapamil were found to be relatively small, and often did not reach statistical significance.

Previous work in this laboratory has shown that cumulative bolus administration of verapamil during halothane anesthesia caused regional dysfunction in the left ventricle.\textsuperscript{9} In the present study, the continuous infusion of verapamil during isoflurane anesthesia caused significant post-systolic shortening in the apical region of the left ventricle. This is particularly obvious when pressure-length loops are examined (fig. 3). In the basal region of the left ventricle, the small amount of PSS (6\%) that was present in the control state was significantly increased (to 16\%) by verapamil. It must be noted that, in this region, a small amount of PSS (about 5–6\%) is frequently present.\textsuperscript{12,13}

Post-systolic shortening is usually attributed to myocardial ischemia,\textsuperscript{7,13,14,15} and has been observed when nitrous oxide was added to fentanyl and sufentanil in the presence of critical coronary artery stenosis.\textsuperscript{11} In the present study, PSS occurred at a time when coronary perfusion pressure was well maintained, and the 10\% reduction of coronary blood flow which occurred with verapamil was not statistically significant. A similar insignificant effect of low dose verapamil during isoflurane anesthesia has been reported by Campos and Kapur.\textsuperscript{10}

Thus, PSS was unlikely to have been caused by myocardial ischemia. Because total LAD coronary blood flow, and not its regional distribution, was measured, undetected redistribution away from the subendocardium could have taken place. However, diastolic wall tension is unlikely to have increased enough to have caused significant redistribution of subendocardial blood flow, and, hence, ischemia, as there was only a small increase in LVEDP (1 mmHg) associated with
small increases in end-diastolic segment length. It must be stressed that, in previous studies, large increases in LVEDP and end-diastolic length in response to deepening halothane anesthesia were observed, and did not cause post-systolic shortening unless critical coronary artery constriction was present.

Another possible cause of PSS is ischemic damage induced by coronary artery dissection. If this was the case, PSS should have been observed in the LAD territory in the control stage (isoflurane alone) which was recorded 1 h after the end of surgery and implantation of the ultrasonic length detectors. This was not the case. In our experience with this model, PSS does not occur spontaneously as a consequence of deterioration of the preparation with the passage of time, and careful coronary artery dissection does not cause regional dysfunction. Indeed, in three animals in which the LAD artery was not dissected, regional dysfunction was also observed after verapamil. It must also be stressed that higher concentrations of isoflurane alone, do not cause regional dysfunction.‡‡

We would, therefore, argue that PSS in the apex of the left ventricle was not caused by ischemia or by coronary artery damage, but was due to an interaction between verapamil and isoflurane resulting in a delay in the onset of contraction and relaxation. Indeed, in the apical region, activation (the start of shortening) was delayed by about 20 ms, and relaxation (the start of lengthening) by about 50 ms. In contrast, in the upper part of the left ventricle, activation was delayed by only 5 ms and relaxation by 20 ms. The greater delay in activation (20 ms vs. 5 ms) and relaxation (50 ms vs. 20 ms) observed in the apical region could explain the small amount of systolic lengthening and the substantial amount of PSS in the apical region. The regional delay in relaxation may be partly responsible for the observed impairment of global relaxation, demonstrated by reduced peak negative dP/dt, and prolonged T relax.

Although halothane had been discontinued for at least 1 h before the start of study of the interaction between isoflurane and verapamil, some residual effect of halothane cannot be excluded. Indeed, Spiss et al. have shown that, for 2 h after discontinuation of halothane, vascular responsiveness remains depressed. However, any effect of halothane would be expected to have been greater at the time that control measurements were taken, and smaller when the interaction verapamil-isoflurane was recorded. This would have led to underestimation, rather than overestimation, of this interaction.


Serruys et al. interpreted the changes in wall motion that they observed in man after intracoronary nifedipine as delayed activation and relaxation. If the regional dysfunction we observed was due to a delay in activation, either a delay in the arrival of the electrical impulse or delay in the coupling between excitation and contraction may have been responsible. We favour the latter, as neither isoflurane nor verapamil affect ventricular conduction. Both calcium channel antagonists and inhalational anesthetics interfere with the movement of calcium ions either into or within the myocyte; these ion movements are intimately involved with all phases of contraction. From a theoretical standpoint, then, it is not surprising that this drug combination should have a potent effect on the process of excitation-contraction-relaxation. Recent work by Lynch suggests that decreased Ca⁺⁺ entry contributes little to the negative inotropy of isoflurane, while an alteration in myocardial sarcoplasmic reticulum uptake/release may play an important role. Further electrophysiological studies at the cellular level, in the presence of verapamil and isoflurane, are needed to test this hypothesis. That dysfunction has not been reported by other groups previously is not surprising. Unless pressure-length loops or fast recordings, including aortic blood flow, are obtained, the exact timing of end-ejection cannot be determined with certainty, and total shortening may easily be reported as systolic shortening, even though a substantial proportion of shortening occurred after the end of ejection.

Dysynchrony of ventricular contraction impairs its overall performance. If shortening occurs when relaxation should be taking place, coronary blood flow may be decreased, compromising oxygen supply to the affected (dysynchronous) region. If coronary blood flow is already compromised, adding verapamil to isoflurane could result in a worsening of regional ischemia.

In summary, the addition of verapamil to isoflurane results in a reduction in global performance of the LV, and impairment of regional contraction, especially in the territory of the LAD.

The disturbance of contraction is characterized by a delay in regional shortening and relaxation which will result in dysynchrony, characterized by paradoxical systolic lengthening (bulge) and post-systolic shortening, both of which reduce the efficiency of global contraction. Underlying dysfunction may be expected to be worsened with this drug combination, with the additional possibility of worsening of preexisting oxygen supply/demand imbalance.

References

1. Kapur PA, Bloor BC, Flack WE, Olewine SK: Comparison of cardiovascular responses to verapamil during enflurane, isoflu-
REGIONAL MYOCARDIAL FUNCTION WITH ISOFLURANE/VERAPAMIL